DMAC (DiaMedica Therapeutics Inc.) stock: $9.36, $504.7M market cap, $43.5M cash, $461.2M EV, $583.1M fully diluted market cap. Next expected readout: Dec-26. Lead program: Recombinant human tissue kallikrein (Acute Stroke), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS). Our lead candidate DM199 (rinvecalinase alfa), is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (rhKLK1) protein to be clinically studied in patients and has been granted Fast Track Designation by the U.S.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 2/3 · ActiveModality: recombinant protein (enzyme)
Aliases rinvecalinase alfa, rhKLK1
Target KLK1 (tissue kallikrein-1)
Indications
acute ischemic stroke (AIS)(Phase 2/3)
preeclampsia (PE)(Phase 2)
fetal growth restriction (FGR)(Phase 2)
Catalysts
— September/October 2026
— end of 2026
Status note Lead product candidate; first pharmaceutically active recombinant form of human tissue kallikrein-1 (KLK1), a serine protease enzyme. AIS: Phase 2/3 adaptive ReMEDy2 trial ongoing (site activation/enrollment slower than expected). PE: Phase 2 investigator-sponsored proof-of-concept trial at Tygerberg Hospital, Cape Town; Part 1a completed June 2026 (sustained reductions in maternal blood pressure reported). FGR: Part 3 of same IST. Prior clinical hold lifted June 2023.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.